Dentistry News
-
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease and Pneumonia Announcement of Topline Safety, Tolerability and Immunogenicity Results from Both the Phase 1 and 2 Portions of the VAX-24 Phase 1/2 Study Expected by the End of 2022 Initiation of ...
-
Vaxcyte to Present at the Jefferies Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ET / 5:30 a.m. PT. A live webcast of the ...
-
Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST, at Rue Granbonpré 11, Building H, 1435 ...
-
Vaxcyte to Participate in Upcoming Investor Conferences in May
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: BofA Securities 2022 Healthcare Conference May 10-13, 2022; Las Vegas, NV Fireside chat will ...
-
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET. A live webcast of the presentation can be ...
-
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
-
MatTek Announces Production and Shipping of EpiOral Tissues from European Facility to Better Service the Wider Market
MatTek Life Sciences will produce and distribute EpiOral from its production facility in Slovakia, continuing the BICO groups’ focus on providing on-demand tissues to the European market. MatTek Life Sciences, a Boston-area tissue engineering company and a part of the BICO Group, announced today its European facility in Bratislava, Slovakia, will begin producing and shipping EpiOral, a ...
-
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system Surgical Innovations’ new YelloPort Elite™ 5mm, with reusable trocar and canula, reduces cost and waste generated when compared with traditional fully single use Port Access Systems Developed with CMR Surgical, the port access system is the latest addition to Surgical Innovation’s ...
-
Align Technology Receives Top Spots on Institutional Investor’s 2022 All-America Executive Team and Most Honored Company Lists
TEMPE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry today announced top-tier recognition for three executives, ...
-
FDA clears Sonavex’s ultrasound blood flow monitor
Sonavex scored FDA clearance for its technology that uses ultrasound imaging and deep learning to deliver blood flow data on demand. The EchoSure system is cleared for use with the company’s EchoMark bioresorbable tissue markers, which got the agency’s nod in June. “The key goal is to be able to detect the problems associated with microvascular and vascular surgeries with ...
-
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to ...
-
Eg Technology And Health Enterprise East Announce Winners Of The 2021 Innovation Voucher Award
Following the success of the 2020 Innovation Voucher Award, won by Mr Ryan Mathew and Dr Heiko Wurdak for their Mini-brain benchtop test, eg technology and Health Enterprise East (HEE) are pleased to announce, not one, but two joint winners of this year’s Innovation Voucher Award. Having received numerous applications covering a fascinating range of emerging medical technologies, this ...
-
Align Technology Announces Record Fourth Quarter and Fiscal 2021 Financial Results
Strengthens Align digital platform with major installed base milestones including 12M Invisalign patients, 68K iTero scanners, and 47K exocad software licenses 2021 total revenues up 59.9% to a record $4.0 billion, operating margin of 24.7%, in line with guidance 2021 revenue growth for the second half was 30.5% compared to 2020, at high-end of 20% to 30% target, in line with guidance 2021 ...
-
Align Technology Announces Settlement of Outstanding Litigation With 3Shape A/S
TEMPE, Ariz., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has settled its longstanding patent infringement and antitrust ...
-
Align Technology Continues to Revolutionize Orthodontic and Restorative Dental Treatment Planning With Invisalign System Innovations For the Align Digital Platform That Enhance Practice Efficiency, Doctor-Patient Engagement, and Treatment Outcomes
ClinCheck Live Update for 3D controls enables real-time ClinCheck treatment plan modifications that improve practice productivity significantly, while also improving quality of treatment plans Invisalign Practice App provides mobile integration with the Invisalign Doctor Site (IDS) and enables doctors to manage their practice at their fingertips. Invisalign Personalized Plan (IPP) ...
-
Time critical delivery of biowaste decontamination systems completed at UK COVID-19 vaccine production facility
Suncombe has designed, built and delivered high specification biowaste effluent decontamination systems (EDS) in an extremely short timeframe to support the expanding Covid-19 vaccine production programme of a global manufacturer in the United Kingdom. To complete this work the company has constructed new vaccine production areas, each of which required a dedicated decontamination system for BSL3 ...
By Suncombe Ltd
-
T,C&A Lab Declares Capability of Biomedical Materials Testing
Since the last few decades, biomedical materials have been extensively used in a lot of medical applications, such as tissue scaffolds, wound care, regenerative dentistry, bone graft, implantable devices and cosmetic surgery. Earlier this month, T,C&A Lab, a branch of Alfa Chemistry, announces to provide biomedical material testing service for customers worldwide who would like to ensure ...
-
Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to ...
-
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today ...
-
Align Technology to Announce Fourth Quarter and 2021 Results on February 2, 2022
TEMPE, Ariz., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and 2021 financial results on ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you